CEA-Scan using antibody directed against carcinoembryonic antigen data

IMMU (Morris Plains, N.J.) reported Phase III data in 208 patients, with 60 percent accuracy in predicting tumor resectability using the CEA-Scan imaging agent. Computed tomography (CT) gave 47 percent predictive accuracy in these patients.

The company's product was correct more often than CT, 69 percent versus 31 percent, when the two methods differed. When both procedures indicated that the tumor was not operable, the accuracy of the prediction was 94 percent. ...